Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume – What’s Next?

Pharming Group (NASDAQ:PHAR) shares saw unusually-strong trading volume on Monday . Approximately 5,632 shares were traded during trading, a decline of 9% from the previous session’s volume of 6,179 shares.The stock last traded at $8.39 and had previously closed at $8.65.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Jefferies Financial Group began coverage on shares of Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price for the company. Oppenheimer increased their price objective on Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a report on Friday, March 14th. Finally, HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research report on Thursday, March 20th.

Pharming Group Trading Up 2.7 %

The stock has a market cap of $580.64 million, a price-to-earnings ratio of -32.83 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The business has a 50-day simple moving average of $8.80 and a two-hundred day simple moving average of $8.68.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The firm had revenue of $92.70 million for the quarter, compared to the consensus estimate of $76.67 million. As a group, research analysts forecast that Pharming Group will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 47,997 shares of the company’s stock after acquiring an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 as of its most recent filing with the SEC. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.